share_log

Tonix Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q:2024财年二季报
美股SEC公告 ·  08/16 17:23

Moomoo AI 已提取核心信息

Tonix Pharmaceuticals Holding Corp. (Tonix) reported financial results for the quarter ended June 30, 2024. The company recognized revenue of $2.2 million, primarily from the sale of two marketed products, Zembrace SymTouch and Tosymra, acquired in July 2023. Cost of sales was $3.4 million, including inventory write-downs of approximately $1.7 million. Research and development expenses decreased by 56% to $9.7 million, due to reduced clinical, non-clinical, and manufacturing expenses. General and administrative expenses increased by 7% to $7.5 million, attributed to higher financial reporting and sales and marketing costs. The company recorded a non-cash impairment charge of $58.9 million related to property, equipment, goodwill, and intangible assets. The net loss for the quarter was $78.8 million, a 177% increase from the previous year's $28.4 million. Tonix's cash resources are...Show More
Tonix Pharmaceuticals Holding Corp. (Tonix) reported financial results for the quarter ended June 30, 2024. The company recognized revenue of $2.2 million, primarily from the sale of two marketed products, Zembrace SymTouch and Tosymra, acquired in July 2023. Cost of sales was $3.4 million, including inventory write-downs of approximately $1.7 million. Research and development expenses decreased by 56% to $9.7 million, due to reduced clinical, non-clinical, and manufacturing expenses. General and administrative expenses increased by 7% to $7.5 million, attributed to higher financial reporting and sales and marketing costs. The company recorded a non-cash impairment charge of $58.9 million related to property, equipment, goodwill, and intangible assets. The net loss for the quarter was $78.8 million, a 177% increase from the previous year's $28.4 million. Tonix's cash resources are expected to fund operations into the third quarter of 2024, but not beyond. The company continues to seek additional funding and may need to scale back or eliminate some operations if additional funds are not secured. Tonix's stock is at risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement. The company's future capital requirements will depend on various factors, including research and development progress, regulatory outcomes, and the ability to develop markets for its product candidates.
Tonix Pharmaceuticals控股公司(Tonix)报告了2024年6月30日结束的季度的财务业绩。公司主要通过销售两种在2023年7月收购的市场产品Zembrace SymTouch和Tosymra,实现了220万美元的营业收入。销售成本为340万美元,其中包括约170万美元的库存减值。由于减少了临床、非临床和制造方面的开支,研发费用减少了56%至970万美元。总部和行政费用增长了7%至750万美元,归因于更高的财务报告和销售与营销成本。公司记录了一笔5890万美元的非现金减值损失,相关资产包括财产、设备、商誉和无形资产。本季度净亏损为7,880万美元,比去年同期增长177%的2...展开全部
Tonix Pharmaceuticals控股公司(Tonix)报告了2024年6月30日结束的季度的财务业绩。公司主要通过销售两种在2023年7月收购的市场产品Zembrace SymTouch和Tosymra,实现了220万美元的营业收入。销售成本为340万美元,其中包括约170万美元的库存减值。由于减少了临床、非临床和制造方面的开支,研发费用减少了56%至970万美元。总部和行政费用增长了7%至750万美元,归因于更高的财务报告和销售与营销成本。公司记录了一笔5890万美元的非现金减值损失,相关资产包括财产、设备、商誉和无形资产。本季度净亏损为7,880万美元,比去年同期增长177%的2,840万美元。尽管Tonix公司的现金资源预计可支持运营至2024年第三季度,但无法支持更长时间。如果无法获得额外资金,该公司将继续寻求额外的融资,并可能需要缩减或取消一些运营。Tonix公司的股票面临被Nasdaq摘牌的风险,因为未能符合最低标价要求。该公司未来的资本需求将取决于各种因素,包括研发进展、监管结果以及发展其产品候选者市场的能力。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息